• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.67% Nasdaq Down1.00%

    More On VLA.AX

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Viralytics Limited (VLA.AX)

    -ASX
    0.75 Down 0.01(0.67%) Apr 29, 1:59AM EDT
    ProfileGet Profile for:
    Viralytics Limited
    66 Hunter Street
    Suite 305
    Sydney, NSW 2000
    Australia - Map
    Phone: 61 2 9988 4000
    Fax: 61 2 8068 6038
    Website: http://www.viralytics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Viralytics Limited, a biotechnology company, engages in developing oncolytic immunotherapy treatments for a range of cancers in Australia. Its lead investigational product is CAVATAK, a proprietary formulation of the common cold Coxsackievirus Type A21 that is in Phase II clinical trial for the treatment of late-stage melanoma; Phase ½ multi-dose intravenous clinical trial for late-stage melanoma, non-small cell lung, bladder, and prostate cancer; Phase I clinical trial for non-muscle invasive bladder cancer; and Phase Ib combination clinical trial for late-stage melanoma. The company is also conducting various preclinical programs on CAVATAK for the treatment of breast, multiple myeloma, pancreatic, and malignant glioma cancer, as well as for acute myeloid leukemia and chronic lymphocytic leukemia. In addition, it develops EVATAK to treat ovarian, prostate, and gastric cancer. The company has clinical trial collaboration agreement with Merck & Co., Inc. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Viralytics Limited

    Key Executives 
     PayExercised
    Dr. Malcolm L. McColl BVSc(Hons), MBA,
    Chief Exec. Officer, Managing Director and Exec. Director
    505.00KN/A
    Prof. Darren Shafren B.Sc (Hons I) Ph.D.,
    Chief Scientific Officer
    N/AN/A
    Mr. Robert Vickery ,
    Chief Financial Officer
    N/AN/A
    Ms. Sarah Prince BA, LLB, ACIS, Grad Dip Corp Gov,
    Company Sec.
    N/AN/A
    Dr. Jennifer Rosenthal Ph.D.,
    Director of Regulatory Affairs
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.